Full Text View
Tabular View
No Study Results Posted
Related Studies
Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis
This study has been terminated.
( efalizumab was withdrawn from market; full 2 years follow-up only 14 patients )
Study NCT00184366   Information provided by Norwegian University of Science and Technology

First Received on September 13, 2005.   Last Updated on January 18, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Plaque Psoriasis
Additional conditions recognized in this trial
Psoriasis
More general conditions related to this trial
Skin Diseases
Skin Diseases, Papulosquamous
Interventions listed in this trial
efalizumab
Sponsors listed in this trial
Norwegian University of Science and Technology


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services